Helicobacter pylori arylamine N-acetyltransferase and urease (HpNAT/Urease)

Helicobacter pylori arylamine N-acetyltransferase (HpNAT) and urease are two distinct enzymes produced by the bacterium Helicobacter pylori that play critical roles in its survival and pathogenesis within the human stomach. Urease is a nickel-dependent enzyme that catalyzes the hydrolysis of urea into ammonia and carbon dioxide, a process essential for neutralizing gastric acid and allowing the bacteria to colonize the acidic environment of the stomach. HpNAT is a transferase involved in the acetylation of arylamine drugs and carcinogens, potentially influencing the bacterium's response to xenobiotics and contributing to gastric carcinogenesis. Both enzymes are considered significant therapeutic targets; urease is the primary target for diagnostic tests like the urea breath test and is a focus for developing novel anti-Helicobacter agents, while HpNAT is studied for its role in drug metabolism and bacterial survival. Inhibiting these enzymes can impair the bacterium's ability to maintain pH homeostasis and metabolize essential compounds, thereby aiding in the eradication of H. pylori infections.

Other names

HpNATArylamine acetyltransferaseUrease alpha subunitUrease beta subunitUreAUreB

Urease inhibition (competitive or non-competitive), NAT inhibition (acetylation blockade)